Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527910) titled 'A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD' on April 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Regeneron Pharmaceuticals
Condition:
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Intervention:
Drug: ALN-PNP
Drug: Tirzepatide
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 20, 2026
Target Sa...